Premium
Chronic administration of the somatostatin analogue SMS 201–995 does not lead to endogenous antibody formation
Author(s) -
FUESSL H. S.,
DOMIN J.,
ANDERSON J. V.,
BLOOM S. R.
Publication year - 1987
Publication title -
alimentary pharmacology and therapeutics
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 3.308
H-Index - 177
eISSN - 1365-2036
pISSN - 0269-2813
DOI - 10.1111/j.1365-2036.1987.tb00605.x
Subject(s) - endogeny , somatostatin , medicine , endocrinology , somatostatin analogue , endocrine system , antibody , peptide hormone , octreotide , subcutaneous injection , incubation , immunology , receptor , hormone , chemistry , biochemistry
SUMMARY Plasma samples of seven patients with gut and pancreatic endocrine tumours who have been on long‐term treatment with a long‐acting somatostatin analogue (SMS 201‐995) were investigated for endogenous antibodies to the peptide by incubation with radiolabelled SMS 201–995. The duration of treatment with the somatostatin analogue was between 9 and 26 months and the dose from 100 to 300μg day −1 . In none of the patients could antibodies to SMS be detected. The effect of this somatostatin analogue is unlikely to be impaired by formation of endogenous antibodies, even after long‐term treatment.